The alternative investment arm of Goldman Sachs Group Inc. has agreed to buy a majority stake in Dutch generic drug maker Synthon from BC Partners.

BC Partners will retain a minority stake in Synthon to support future growth, according to a statement Monday that confirmed an earlier Bloomberg News report. It did not provide financial details. 

Bloomberg News reported earlier that Goldman's unit had beaten other potential buyers for Synthon and could value the drugmaker at about 2 billion euros ($2.1 billion).

Founded in 1991, Synthon International develops and produces generic drugs for therapeutic areas such as oncology, central nervous system and cardiovascular, according to its website. The Netherlands-based company has offices in Argentina, Chile, the Czech Republic, South Korea, Mexico and Spain.

BC Partners acquired a majority stake in Synthon for $750 million in 2019 from the drugmaker's founder, who remained an investor as a minority shareholder. Since then, BC Partners has more than doubled Synthon's operating profit, it said. 

With the latest transaction, the private equity firm has divested €13 billion in assets over the past 18 months, according to Monday's announcement. BC Partners recently sold its majority stake in Canadian security services company GardaWorld. It has also made an IPO of German publisher Springer Nature, sold Italian frozen pasta and bakery products maker Forno d'Asolo, and offloaded a stake in IMA Industria Macchine Automatiche SpA to U.S. merchant bank BDT & MSD Partners. 

The sale of Synthon is expected to close in the second quarter of 2025. BC Partners was advised by Rothschild & Co., Barclays and PwC on the deal.